Medical Device Post-Market Surveillance (PMS) in the Philippines
Ensuring your medical devices remain safe, compliant, and effective within the Philippines’ regulatory environment can be complex. With Andaman Medical’s expert medical device post-market surveillance in the Philippines, we take the burden off your shoulders by managing the entire process for you. From navigating local requirements to monitoring ongoing device performance and safety, we help keep your products compliant, reliable, and positioned for continued market success.
Why Get Medical Device PMS in the Philippines?
Post-market surveillance is about more than simply fulfilling regulatory obligations—it’s essential for safeguarding patient safety, preserving market access, and building lasting trust in your brand.
At Andaman Medical, we provide comprehensive PMS solutions designed to help you confidently navigate the Philippines’ regulatory environment. Leveraging our deep knowledge of local requirements and the medical device sector, we support you in ensuring your device’s safety and compliance, while proactively managing risks, enhancing product quality, and promoting better patient outcomes.
Here’s how Andaman Medical helps you overcome the challenges of medical device post-market surveillance in the Philippines:
Regulatory Compliance
Regulatory Compliance
Post-market surveillance (PMS) is a mandatory requirement by the Ministry of Health to ensure continued safety, effectiveness, and quality of medical devices in the market. Regular monitoring helps maintain compliance with local regulations and avoids penalties.
Early Detection of Issues
Early Detection of Issues
PMS allows for the early identification of potential safety concerns, performance issues, or adverse events related to your device. This proactive approach helps prevent widespread problems and protects patients from harm.
Improvement of Product Quality
Improvement of Product Quality
Continuous monitoring provides valuable feedback on device performance in real-world settings. This information can be used to enhance product design, manufacturing processes, and overall quality, leading to better patient outcomes.
Maintaining Market Authorization
Maintaining Market Authorization
Effective post-market surveillance is critical for maintaining your device’s market authorization. Ongoing compliance with surveillance requirements demonstrates your commitment to product safety and helps avoid the risk of losing regulatory approval.
Building Trust with Healthcare Providers
Building Trust with Healthcare Providers
PMS data helps build confidence among healthcare professionals by providing evidence of ongoing device performance and safety. This trust can lead to increased adoption and recommendation of your products.
Risk Management and Mitigation
Risk Management and Mitigation
PMS helps manufacturers identify and address risks associated with their devices, enabling timely corrective actions and reducing the likelihood of costly recalls, legal issues, and damage to brand reputation.
Medical Device PMS Requirements in the Philippines
In accordance with Annex 5 of the AMDD, the following is required as part of a PMAS in the Philippines:
Importation and/or distribution records
Complaint records
Adverse Event (AE) reporting criteria and reporting format
Field Safety Corrective Action (FSCA) reporting format
All medical device establishments, manufacturers, distributors, importers, exporters, wholesalers must have a Quality Management System (QMS) and relevant documentation in place. This is checked and audited by the Philippines FDA during its routine inspections. The QMS must include an established Risk Management Plan (RMP) and Standard Operating Procedures (SOPs) together with their related forms for Good Storage and Distribution, Complaint Handling, Product Recalls, Medical Device Disposal/Destruction.
IMPORTANT REMINDER
Adverse Event reporting requirements in the Philippines
Adverse events | Report within |
---|---|
Serious threat to public health: Immediately or not later than 48 hours | 48 hours |
Death | 10 days |
Serious deterioration in state of health | 10 days |
Possible death or serious injury if the adverse event were to recur | 30 days |
- An Adverse Event has occurred
- The device is associated with the AE
- The AE led to one of the following outcomes:
- A serious threat to public health
- Death of a patient, user or other person
- No death or serious occurred but the event that might lead to death or serious injury of a patient user or other person if the event recurs.
As part of PMS for medical devices in the Philippines, the evaluator follows up with the reporting person for further information and processes valid reports using CDRRHR-PRSDD-Form 021. If the suspected medical device is registered, the evaluator issues Corrective and Preventive Action (CAPA) to the distributor, manufacturer, or owner about the adverse event/complaint and requires them to conduct corrective action and submit a report. This may lead to the possible issuing of an Advisory or an Advisory plus surveillance or recall of the suspected device.
Any adverse event occurring outside the Philippines do not qualify for reporting to the PFDA, unless the user is Filipino and the device is obtained from the Philippines, or it is otherwise requested. The country of occurrence should be stated.
Navigating post-market surveillance in Philippines can be challenging, but Andaman Medical is here to streamline the process and ensure you stay fully compliant with ease. Connect with our experts today and take the first step toward hassle-free compliance!
Why Choose Andaman Medical for Your Medical Device Post-Market Surveillance in Philippines

Post-Market Surveillance of Medical Devices in the Philippines
The Philippines’ Food and Drug Administration (PFDA) is the local authority responsible for medical devices in the Philippines and requires all medical device manufacturers and distributors (whether importer, exporter or wholesaler) to undertake post-market surveillance (PMS) and have a PMS plan. The Philippines FDA has chosen to adopt the Post-Market Alert System (PMAS) for Defective Devices of the ASEAN Medical Device Directive (AMDD), please read on to understand how post-market surveillance is implemented in the Philippines.
- Home
- Regulatory Services
- Post Market Surveillance
- Philippines
What are the requirements for medical device PMS in the Philippines?
In accordance with Annex 5 of the AMDD, the following is required as part of a PMAS in the Philippines:
1.
Importation and/or distribution records
2.
Complaint records
3.
Adverse Event (AE) reporting criteria and reporting format
4.
Field Safety Corrective Action (FSCA) reporting format
All medical device establishments, manufacturers, distributors, importers, exporters, wholesalers must have a Quality Management System (QMS) and relevant documentation in place. This is checked and audited by the Philippines FDA during its routine inspections. The QMS must include an established Risk Management Plan (RMP) and Standard Operating Procedures (SOPs) together with their related forms for Good Storage and Distribution, Complaint Handling, Product Recalls, Medical Device Disposal/Destruction.
Please note: In the Philippines an importer is the Local Authorized Representative of Foreign Manufacturers please refer to our Registration of Medical Devices in the Philippines for clarification.
Adverse Event reporting requirements in the Philippines
The following medical device associated AEs must be reported to the Philippines FDA:
Adverse events | Report within |
---|---|
Serious threat to public health | 48 hours |
Death | 10 days |
Serious deterioration in state of health | 10 days |
Possible death or serious injury if the adverse event were to recur | 30 days |
Medical Device Companies reporting Adverse Events will need to send their AE report via email to the Director of the Center for Device Regulation Radiation Health and Research (CDRRHR) and the Division Chief of Product Research and Standard Development Division (PRSDD). The FDA evaluator accepts reports from all distributors, manufacturers, owners, end-users of devices using the prescribed format (CDRRHR-PRSDD-Form 0.20). The FDA evaluator validates any adverse event (AE) which meets the three basic reporting criteria listed below:
- An Adverse Event has occurred
- The device is associated with the AE
- The AE led to one of the following outcomes:
- A serious threat to public health
- Death of a patient, user or other person
- No death or serious occurred but the event that might lead to death or serious injury of a patient user or other person if the event recurs.
The evaluator follows up with the reporting person for further information and processes valid reports using CDRRHR-PRSDD-Form 021. If the suspected device is registered, the evaluator issues Corrective and Preventive Action (CAPA) to the distributor, manufacturer or owner about the adverse event/complaint and requires them to conduct corrective action and submit a report. This may lead to the possible issuing of an Advisory or an Advisory plus surveillance or recall of the suspected device.
Any adverse event occurring outside the Philippines do not qualify for reporting to the PFDA, unless the user is Filipino and the device is obtained from the Philippines, or it is otherwise requested. The country of occurrence should be stated.
How Andaman Medical can help you with post-market surveillance in the Philippines
With 6 local offices throughout Southeast Asia, Andaman Medical provides support for your post-market surveillance activities including adverse event and FSCA mandatory reporting. Our local, in-house staff liaise with the Food and Drug Administration to help you maintain compliance once your medical device is placed on the market. Our services include:
- support for your mandatory reporting of Adverse Events and Field Safety Corrective Actions
- identify requirements in medical device directives, standards, and guidance documents to ensure effective implementation of a post-market surveillance system
- evaluate your PMS data to ensure that existing processes and outputs are fully compliant
- monitor and report on any regulatory changes to ensure ongoing compliance